Do different UBE3A missense mutations correlate with specific variations in the severity of cognitive or motor symptoms based on whether they disrupt nuclear versus synaptic localization?
“Do different UBE3A missense mutations correlate with specific variations in the severity of cognitive or motor symptoms based on whether they disrupt nuclear versus synaptic localization?”
Inspired by “Does the specific loss of UBE3A's nuclear function versus its synaptic function drive distinct pathological aspects of Angelman syndrome?” →Summary
The investigation into whether specific UBE3A missense mutations correlate with symptom severity based on their nuclear versus synaptic localization revealed that while the importance of UBE3A compartmentalization is well-established, clinical data has not yet reached the level of granularity required to map specific mutations to distinct clinical phenotypes. Current research identifies nuclear mislocalization as a dominant pathogenic mechanism for Angelman syndrome, often overshadowing granular comparisons between synaptic and nuclear functionality in human subjects. It was surprising to find that while the field acknowledges the distinct physiological roles of nuclear and synaptic UBE3A, most clinical genotype-phenotype studies continue to group mutations by broad functional categories (like deletions versus point mutations) rather than subcellular localization.
The trail
11 steps — 2 thoughts · 2 searches · 2 discoveries · 2 sources · 1 direction changes · 1 dead ends · 1 conclusion
- Thought#1about 24 hours ago
I am investigating whether specific UBE3A missense mutations correlate with symptom severity based on their impact on nuclear versus synaptic localization. I need to determine if the literature distinguishes between these two localization-based mechanisms in terms of clinical outcomes.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Search#2about 24 hours ago
search for studies linking UBE3A missense mutation localization (nuclear vs synaptic) to specific clinical phenotypes in Angelman syndrome.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Discovery#3about 24 hours ago
Research indicates that loss of nuclear UBE3A is a predominant cause of Angelman syndrome in patients with missense mutations, with over 50% of tested mutations resulting in nuclear mislocalization. However, while the literature confirms that nuclear localization is critical for neurodevelopment, it does not currently provide a granular mapping of specific missense mutations to distinct 'nuclear-only' vs 'synaptic-only' clinical severity profiles.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Source#4about 24 hours ago
Studies show that UBE3A localizes to both nuclear and synaptic compartments, with the nuclear switch occurring in the postnatal period, which overlaps with the critical window for symptom emergence.
www.orpha.net/pdfs/data/prj/NL/ID141443NL.pdf - Direction change#5about 24 hours ago
While I found strong evidence that nuclear mislocalization is a major driver of pathology, the current literature focuses on the binary of 'functional vs. non-functional' or 'nuclear vs. total loss' rather than comparing the severity of 'nuclear-disrupting' vs 'synaptic-disrupting' mutations in human patients.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Thought#6about 24 hours ago
I need to determine if there is any evidence that specific missense mutations in UBE3A lead to differential clinical outcomes based on their localization (nuclear vs. synaptic). While previous research confirms nuclear loss is a primary driver, I will investigate if recent genotype-phenotype studies have identified specific mutation-linked symptom variations.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Search#7about 24 hours ago
search for recent genotype-phenotype correlation studies in Angelman syndrome that specifically analyze missense mutations and symptom severity.
www.cell.com/hgg-advances/fulltext/S2666-2477(24)00082-4 - Discovery#8about 24 hours ago
Recent studies, such as Fujimoto et al. (2024), have investigated genotype-phenotype correlations in Angelman syndrome, but these primarily focus on broad categories like deletions versus mutations rather than mapping specific missense mutation localization (nuclear vs. synaptic) to distinct clinical severity profiles.
www.cell.com/hgg-advances/fulltext/S2666-2477(24)00082-4 - Source#9about 24 hours ago
Research confirms that while nuclear UBE3A loss is a predominant cause of Angelman syndrome, the field lacks a granular clinical map that differentiates the severity of 'nuclear-disrupting' versus 'synaptic-disrupting' missense mutations in human patients.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352 - Dead end#10about 24 hours ago
I have reached a point where the current literature confirms the importance of nuclear localization but does not provide the specific clinical data required to correlate individual missense mutations with distinct 'nuclear vs. synaptic' symptom severity profiles.
www.cell.com/hgg-advances/fulltext/S2666-2477(24)00082-4 - Conclusion#11about 24 hours ago
While nuclear UBE3A localization is clearly vital for neurodevelopment, there is currently no clinical map linking specific missense mutations to distinct 'nuclear-only' or 'synaptic-only' severity profiles, suggesting this remains a frontier for future molecular-clinical research.
pmc.ncbi.nlm.nih.gov/articles/PMC8101352
Branches
Follow-up questions spawned
Could CRISPR-engineered organoid models specifically isolate the impact of nuclear-targeted versus synaptic-targeted UBE3A mutations to better predict phenotypic severity?
Answered · CurioRoam Roam Engine